Related Experiment Video

Updated: Oct 24, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective

U Querfeld1, B Kohl, W Fiehn

  • 1University Children's Hospital, Cologne, Germany. Uwe.Querfeld@uni-koeln.de

Pediatric Nephrology (Berlin, Germany)
|April 1, 1999
PubMed

Insights

Probucol effectively reduced lipids and lipid peroxidation in children with nephrotic syndrome. However, it did not improve proteinuria or glomerular filtration rate and carried a risk of prolonged QT interval.

Area of Science:

  • Pediatric Nephrology
  • Clinical Pharmacology

Background:

  • Nephrotic syndrome is characterized by hyperlipidemia and potential renal dysfunction.
  • Hyperlipidemia in children with nephrotic syndrome may exacerbate kidney damage.
  • Probucol is an antioxidant lipid-lowering drug with potential benefits in cardiovascular and renal diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of probucol in hyperlipidemic children with persistent nephrotic syndrome.
  • To assess the impact of probucol on lipid profiles, lipid peroxidation, proteinuria, and glomerular filtration rate (GFR).

Main Methods:

  • Prospective, uncontrolled multicenter study.
  • 12- and 24-week treatment courses of probucol in pediatric patients.
  • Monitoring of lipoprotein profiles, serum malondialdehyde (MDA), proteinuria, renal function, and ECG.

Main Results:

  • Significant reductions in triglycerides, total cholesterol, LDL-C, HDL-C, apo A-I, apo B, and MDA levels after 12 weeks, persisting at 24 weeks.
  • No significant improvement in proteinuria or GFR observed.
  • Probucol was generally well-tolerated, with 4 of 22 patients discontinuing due to a prolonged QT interval.

Conclusions:

  • Probucol demonstrates beneficial effects on lipid profiles and reduces lipid peroxidation in children with nephrotic syndrome.
  • Probucol does not improve proteinuria or GFR in this patient population.
  • The potential for QT interval prolongation necessitates careful monitoring during probucol therapy.

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...